I. A. Mazerkina, V. Evteev, A. Prokofiev, O. V. Muslimova, E. Demchenkova
{"title":"β-Lactam Antibiotics—Drug-Drug Interaction Mediated by Organic Anion Transporters OAT1 and OAT3","authors":"I. A. Mazerkina, V. Evteev, A. Prokofiev, O. V. Muslimova, E. Demchenkova","doi":"10.30895/1991-2919-2020-10-3-177-183","DOIUrl":null,"url":null,"abstract":"Organic anion transporters OAT1 and OAT3 play a key role in elimination of most β-lactam antibiotics. Since nonsteroidal anti-inflammatory drugs, antivirals, antitumor agents, and some other drugs are also substrates of OAT1/3, this enables drug-drug interaction (DDI). The aim of the study was to analyze scientific literature to determine the likelihood and significance of β-lactam antibiotic DDI mediated by organic anion transporters, as well as potential for predicting it. In clinical practice, inhibition of β-lactam antibiotic elimination is used to increase systemic exposition and reduce the cost of antibiotic therapy. OAT inhibitors (cilastatin, betamipron) are used in combination drugs to reduce nephrotoxicity of carbapenems. On the other hand, an increase in the concentration of β-lactams due to OAT inhibition may lead to adverse drug reactions. Therefore, the European Medicines Agency and the Food and Drug Administration recommendations for the development of new drugs state that in the case of significant renal excretion (≥25%) it is necessary to investigate OAT1/3 transport in vitro and calculate inhibition constant Ki and/or half maximal inhibitory concentration IC50 for predicting DDI. One of the main problems is the variability of Ki and IC50 values between laboratories, which requires the development of general recommendations for different transporters as regards methods of determination of these parameters.","PeriodicalId":22286,"journal":{"name":"The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30895/1991-2919-2020-10-3-177-183","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Organic anion transporters OAT1 and OAT3 play a key role in elimination of most β-lactam antibiotics. Since nonsteroidal anti-inflammatory drugs, antivirals, antitumor agents, and some other drugs are also substrates of OAT1/3, this enables drug-drug interaction (DDI). The aim of the study was to analyze scientific literature to determine the likelihood and significance of β-lactam antibiotic DDI mediated by organic anion transporters, as well as potential for predicting it. In clinical practice, inhibition of β-lactam antibiotic elimination is used to increase systemic exposition and reduce the cost of antibiotic therapy. OAT inhibitors (cilastatin, betamipron) are used in combination drugs to reduce nephrotoxicity of carbapenems. On the other hand, an increase in the concentration of β-lactams due to OAT inhibition may lead to adverse drug reactions. Therefore, the European Medicines Agency and the Food and Drug Administration recommendations for the development of new drugs state that in the case of significant renal excretion (≥25%) it is necessary to investigate OAT1/3 transport in vitro and calculate inhibition constant Ki and/or half maximal inhibitory concentration IC50 for predicting DDI. One of the main problems is the variability of Ki and IC50 values between laboratories, which requires the development of general recommendations for different transporters as regards methods of determination of these parameters.
有机阴离子转运体OAT1和OAT3在消除大多数β-内酰胺类抗生素中起关键作用。由于非甾体类抗炎药、抗病毒药物、抗肿瘤药物和其他一些药物也是OAT1/3的底物,这使得药物-药物相互作用(DDI)成为可能。本研究的目的是通过分析科学文献来确定有机阴离子转运体介导β-内酰胺类抗生素DDI的可能性和意义,以及预测它的潜力。在临床实践中,抑制β-内酰胺类抗生素消除被用于增加全身暴露和降低抗生素治疗的成本。OAT抑制剂(西司他汀,倍他米酮)用于联合用药以降低碳青霉烯类药物的肾毒性。另一方面,由于OAT抑制,β-内酰胺的浓度增加可能导致药物不良反应。因此,欧洲药品管理局(European Medicines Agency)和美国食品和药物管理局(Food and Drug Administration)的新药开发建议指出,在肾排泄显著(≥25%)的情况下,有必要研究ooat1 /3的体外转运,并计算抑制常数Ki和/或一半最大抑制浓度IC50,以预测DDI。其中一个主要问题是实验室之间Ki和IC50值的可变性,这就需要针对不同的转运体制定确定这些参数的方法的一般建议。